Ask the Expert: 2026 in Review, What APAC Needs to Know for 2027

2026 was a year of big change for clinical trials. ICH E6(R3) moved into practice, AI arrived in everyday TMF work, the CDISC TMF Standard Model went through community review, and APAC biotechs signed a record number of licensing deals with global partners. Running through all of these is one question: is your TMF oversight strong enough? Join us on December 2nd for a live, conversational session where we look back at what shaped the TMF landscape this year and what APAC sponsors and CROs should prepare for in 2027.

This session is built around your questions. Gillian Gittens, CDISC TMF Steering Committee Member and Trial Interactive Senior Director, eClinical Strategy & Solutions, joined by Avani Amin, Director, Client Solutions at Trial Interactive, will answer them, bringing their global views to the challenges APAC teams face. When you register, share the question you’d most like answered, whether it’s about inspection readiness, sponsor oversight, TMF transfers during licensing and partnerships, or getting ready for the new Standard Model. Seats are limited, so register now and send in your question early.